Bristol-Myers Tests Sprycel in Lung Cancer in New Study
This article is for subscribers only.
Bristol-Myers Squibb Co. started a new trial of leukemia drug Sprycel in patients with lung cancer after the medicine appeared to help cure one man.
Among 34 patients given Sprycel in an earlier study, one man has remained cancer-free for four and a half years, according to research published today in the journal Science Translational Medicine. Only 2 percent of patients survive that long with advanced lung cancer. An analysis showed the man was the only one from the trial they could find that had a type of mutation, called BRAF-Y472C, that Sprycel targets.